Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/jch.13925

http://scihub22266oqcxt.onion/10.1111/jch.13925
suck pdf from google scholar
32627330!7362072!32627330
unlimited free pdf from europmc32627330    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32627330      J+Clin+Hypertens+(Greenwich) 2020 ; 22 (7): 1120-1126
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19 and arterial hypertension: Hypothesis or evidence? #MMPMID32627330
  • Tadic M; Cuspidi C; Grassi G; Mancia G
  • J Clin Hypertens (Greenwich) 2020[Jul]; 22 (7): 1120-1126 PMID32627330show ga
  • Investigations reported that hypertension, diabetes, and cardiovascular diseases were the most prevalent comorbidities among the patients with coronavirus disease 2019 (COVID-19). Hypertension appeared consistently as the most prevalent risk factors in COVID-19 patients. Some investigations speculated about the association between renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and increased mortality in these patients. This raised concern about the potential association between hypertension (and its treatment) and propensity for COVID-19. There are only a few follow-up studies that investigated the impact of comorbidities on outcome in these patients with conflicting findings. Hypertension has been proven to be more prevalent in patients with an adverse outcome (admission in intensive care unit, use of mechanical ventilation, or death). So far, there is no study that demonstrated independent predictive value of hypertension on mortality in COVID-19 patients. There are many speculations about this coronavirus and its relation with different risk factors and underlying diseases. The aim of this review was to summarize the current knowledge about the relationship between hypertension and COVID-19 and the role of hypertension on outcome in these patients.
  • |Adult[MESH]
  • |Aged[MESH]
  • |Aged, 80 and over[MESH]
  • |Angiotensin Receptor Antagonists/adverse effects[MESH]
  • |Angiotensin-Converting Enzyme Inhibitors/adverse effects[MESH]
  • |COVID-19/*epidemiology/mortality/*physiopathology/virology[MESH]
  • |Cardiovascular Diseases/epidemiology[MESH]
  • |Comorbidity[MESH]
  • |Diabetes Mellitus/epidemiology[MESH]
  • |Disease Susceptibility[MESH]
  • |Female[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Hypertension/drug therapy/*epidemiology[MESH]
  • |Intensive Care Units/statistics & numerical data[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Outcome Assessment, Health Care[MESH]
  • |Predictive Value of Tests[MESH]
  • |Prevalence[MESH]
  • |Renin-Angiotensin System/drug effects/immunology[MESH]
  • |Respiration, Artificial/statistics & numerical data[MESH]
  • |Risk Factors[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box